 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Pronunciation | ⫽ɪbrɪtuːmoʊmæb taɪʌksɛtæn⫽[1] |
| Trade names | Zevalin |
| Other names | Ibritumomab tiuxetan |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | intravenous |
| Legal status | |
| Legal status |
|
  (what is this?) (verify) | |
Ibritumomab, sold under the trade name Zevalin, is a medication used to treat non-Hodgkin's lymphoma.[2] It is used following treatment with rituximab.[3] It is given by gradual injection into a vein.[2]
Common side effects include low red blood cells, low white blood cells, low platelets, weakness, fever, and nausea.[3] Other side effects may include Stevens-Johnson syndrome and myelodysplastic syndrome.[2] It is a monoclonal antibody attached to the radioactive element yttrium-90.[3] The monoclonal antibody binds to CD20 found on B cells.[3]
Ibritumomab was approved for medical use in the United States in 2002 and Europe in 2004.[2][3] In the United States it costs 59,300 USD for a dose as of 2021.[4] Use was not recommended by NHS Scotland in 2007 due to insufficient evidence of cost benefit.[5]
References
edit- ^ "Ibritumomab Tiuxetan". National Cancer Institute. 26 February 2008. Archived from the original on 9 July 2020. Retrieved 25 July 2020.
- ^ a b c d e "Ibritumomab Monograph for Professionals". Drugs.com. Archived from the original on 26 February 2021. Retrieved 24 November 2021.
- ^ a b c d e f "Zevalin". Archived from the original on 11 November 2020. Retrieved 24 November 2021.
- ^ "Y-90 Zevalin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 24 November 2021.
- ^ "ibritumomab tiuxetan (Zevalin)". Scottish Medicines Consortium. Archived from the original on 11 December 2021. Retrieved 24 November 2021.